164. Tc 99m tilmanocept (CD206 bio-targeted) shows superiority over colloidal agents when utilized in intraoperative lymphatic mapping of breast cancer patients in two key clinical performance characteristics (patient localization and degree of localization)

2012 ◽  
Vol 38 (9) ◽  
pp. 787
Author(s):  
F.O. Cope ◽  
W.L. Metz ◽  
B. Potter ◽  
R.D. Hartman ◽  
M.T. Joy ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Lymphatic Mapping ◽  
Clinical Performance ◽  
Performance Characteristics ◽  
Breast Cancer Patients ◽  
Patient Localization

Where to look for sentinel node in breast cancer?

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 2560-2560
Author(s):  
Anton J. Scharl ◽  
Andreas Düran ◽  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Sentinel Node ◽  
Cancer Patients ◽  
Lymphatic Mapping ◽  
False Negative ◽  
False Negative Rate ◽  
Breast Cancer Patients ◽  
Standard Methods

2560 Background: It has been observed, that the caudal Axilla on the border to pectoralis muscle is predicive for the sentinel node. The sono-morphology of lymph nodes has been the subject of multiple publications, usually dealing with malignant melanoma. In the context of sentinel lymph node biopsy (SLNB) in breast cancer patients, the following study examines the feasibility of the sonographic differentiation of the Sentinel lymph node (SLN) from neighboring non-SLNs and whether sentinel-ultrasound-needle localization (SUN) is a useful addition or alternative to current methods of “lymphatic mapping”. Methods: During a prospective study performed from 1/2003 to 9/2005 including 404 breast cancer patients (Tis-T4), the SLNB was performed using patent blue+/- 99Tc-Nanocoll. In addition to and independent of this method, the axilla was sonographically examined for “reactive” lymph nodes n=180 pt. (Siemens Elegra 7.5 MHz). The “reactivity” of the nodes was quantified using an index , which allowed the comparison of adjacent nodes. The most “reactive” lymph node in the caudal axilla was identified as the “Ultrasound-Sentinel-Node”(US-SLN) and has been marked with a wire. Results: In 180 patients the SLN was localized using the standard methods as well as (SUN). The was no difference in detection rates of US-SLN and the standard methods in tumor-free nodes(SLN-). However, for patients with axillary metastases (SLN+) SUN provided superior detection rate (99,1%). The false-negative-rate was reduced from 10,7 % to 1,3%. This was attributed to the embolization of lymph vessels afferent to the metastasized (SLN+) node causing a bypass of the “lymphatic mapping” and inhibiting detection. Conclusions: The SUN–Method is comparable to “lymphatic mapping” in tumor free nodes (SLN -). If SLN is metastasized (SLN+) - SUN is superior to the standard methods in sensitivity and specificity (80%) and the false-negative-rate can be reduced. Systematic axilla sonography is an effective method for the SLN-Localisation, and offers an excellent method for quality control during SLNB.

The Safety of Lymphatic Mapping in Pregnant Breast Cancer Patients Using Tc-99m Sulfur Colloid

2004 ◽  
Vol 10 (6) ◽  
pp. 492-495 ◽  
Author(s):  
Angela Keleher ◽  
Richard Wendt ◽  
Ebrahim Delpassand ◽  
Anne Marie Stachowiak ◽  
Henry M. Kuerer
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Lymphatic Mapping ◽  
Breast Cancer Patients ◽  
Sulfur Colloid

scholarly journals Clinical and technical evaluation of ACS™BR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA 15-3 assays

1997 ◽  
Vol 43 (4) ◽  
pp. 585-593 ◽  
Author(s):  
Gijsbert G Bon ◽  
Silvia von Mensdorff-Pouilly ◽  
Peter Kenemans ◽  
Gerard J van Kamp ◽  
Rob A Verstraeten ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Clinical Performance ◽  
Linear Regression Analysis ◽  
Breast Disease ◽  
Breast Cancer Patients ◽  
Serum Samples ◽  
Cancer Disease ◽  
Healthy Women ◽  
Technical Evaluation

Abstract The mucin glycoprotein-detecting assay CA 15-3 is a valuable tool for monitoring the course of disease in breast cancer patients. Assays of CA 15-3 are based on the use of two MAbs to polymorphic epithelial mucin (PEM). We evaluated the technical and clinical performance of the Chiron ACSTM BR, an automated competitive chemiluminescence assay using a single MAb, B27.29, and compared the assay’s results with those of the Centocor CA 15-3 RIA, the Abbott IMx CA 15-3, and the Boehringer Mannheim Enzymun-Test CA 15-3. The study population consisted of 253 healthy women, 66 patients with benign breast disease, 168 breast cancer patients, and 76 patients with other carcinomas. In the technical evaluation, we assessed the precision and linearity on dilution of the ACS BR assay. Cutoff values (upper limits of values seen in healthy subjects) were determined for all four assays. Agreement between the assays was studied by linear regression analysis. The ACS BR assay gave within- and between-assay CVs of 2.2% and 3.9%, respectively. Three samples from healthy women gave discordant values by ACS BR and were not included in the calculations. All four assays exhibit a highly similar pattern when monitoring breast cancer disease; the closest agreement of values was obtained between ACS BR and Centocor CA 15-3. We conclude that the ACS BR assay is a fast and reliable immunoassay for measuring PEM in serum. Although it detects a slightly different epitope on the PEM molecule than is targeted in other assays, for cancer serum samples it agreed better with the original Centocor CA 15-3 assay than did the other two CA 15-3 assays tested.

Rationale for superficial injection techniques in lymphatic mapping in breast cancer patients

2004 ◽  
Vol 87 (4) ◽  
pp. 153-156 ◽  
Author(s):  
Omgo E. Nieweg ◽  
Susanne H. Estourgie ◽  
Maartje C. van Rijk ◽  
Bin. B.R. Kroon
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Lymphatic Mapping ◽  
Breast Cancer Patients ◽  
Injection Techniques
Sign in / Sign up

Export Citation Format

Share Document